Pierre Lapalme - Net Worth and Insider Trading

Pierre Lapalme Net Worth

The estimated net worth of Pierre Lapalme is at least $2 Million dollars as of 2024-11-13. Pierre Lapalme is the Director of Biomarin Pharmaceutical Inc and owns about 31,650 shares of Biomarin Pharmaceutical Inc (BMRN) stock worth over $2 Million. Pierre Lapalme is also the Director of Insys Therapeutics Inc and owns about 9,000 shares of Insys Therapeutics Inc (INSYQ) stock worth over $378. Details can be seen in Pierre Lapalme's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Pierre Lapalme has not made any transactions after 2015-03-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Pierre Lapalme

To

Pierre Lapalme Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Pierre Lapalme owns 2 companies in total, including Insys Therapeutics Inc (INSYQ) , and Biomarin Pharmaceutical Inc (BMRN) .

Click here to see the complete history of Pierre Lapalme’s form 4 insider trades.

Insider Ownership Summary of Pierre Lapalme

Ticker Comapny Transaction Date Type of Owner
INSYQ Insys Therapeutics Inc 2018-03-05 director
BMRN Biomarin Pharmaceutical Inc 2015-03-03 director

Pierre Lapalme Latest Holdings Summary

Pierre Lapalme currently owns a total of 2 stocks. Among these stocks, Pierre Lapalme owns 31,650 shares of Biomarin Pharmaceutical Inc (BMRN) as of March 3, 2015, with a value of $2 Million and a weighting of 99.98%. Pierre Lapalme also owns 9,000 shares of Insys Therapeutics Inc (INSYQ) as of May 24, 2013, with a value of $378 and a weighting of 0.02%.

Latest Holdings of Pierre Lapalme

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BMRN Biomarin Pharmaceutical Inc 2015-03-03 31,650 66.12 2,092,698
INSYQ Insys Therapeutics Inc 2013-05-24 9,000 0.04 378

Holding Weightings of Pierre Lapalme


Pierre Lapalme Form 4 Trading Tracker

According to the SEC Form 4 filings, Pierre Lapalme has made a total of 0 transactions in Biomarin Pharmaceutical Inc (BMRN) over the past 5 years. The most-recent trade in Biomarin Pharmaceutical Inc is the sale of 20,000 shares on March 3, 2015, which brought Pierre Lapalme around $2 Million.

According to the SEC Form 4 filings, Pierre Lapalme has made a total of 0 transactions in Insys Therapeutics Inc (INSYQ) over the past 5 years. The most-recent trade in Insys Therapeutics Inc is the acquisition of 9,000 shares on May 24, 2013, which cost Pierre Lapalme around $31,170.

Insider Trading History of Pierre Lapalme

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Pierre Lapalme Trading Performance

GuruFocus tracks the stock performance after each of Pierre Lapalme's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Pierre Lapalme is 26.65%. GuruFocus also compares Pierre Lapalme's trading performance to market benchmark return within the same time period. The performance of stocks bought by Pierre Lapalme within 3 months outperforms 3 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Pierre Lapalme's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Pierre Lapalme

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
6 out of 6 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 5.58 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 4.4 LIMIT LIMIT LIMIT LIMIT LIMIT

Pierre Lapalme Ownership Network

Ownership Network List of Pierre Lapalme

No Data

Ownership Network Relation of Pierre Lapalme

Insider Network Chart

Pierre Lapalme Owned Company Details

What does Insys Therapeutics Inc do?

Who are the key executives at Insys Therapeutics Inc?

Pierre Lapalme is the director of Insys Therapeutics Inc. Other key executives at Insys Therapeutics Inc include director & Chief Executive Officer Andrew G Long , Chief Legal Officer & Gen Cnsl Mark E Nance , and 10 percent owner John N Kapoor .

Insys Therapeutics Inc (INSYQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Insys Therapeutics Inc (INSYQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Insys Therapeutics Inc (INSYQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Insys Therapeutics Inc (INSYQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Insys Therapeutics Inc Insider Transactions

No Available Data

Pierre Lapalme Mailing Address

Above is the net worth, insider trading, and ownership report for Pierre Lapalme. You might contact Pierre Lapalme via mailing address: First Horizon Pharmaceutical Corp, 660 Hembree Pkwy Ste 106, Roswell Ga 30076.